TSHA-102 Gene Therapy for Rett Syndrome

(ASPIRE Trial)

This trial tests a new gene therapy called TSHA-102 for girls with typical Rett syndrome, a rare genetic disorder affecting brain development. The main goal is to determine if this treatment is safe and effective when administered as a single injection into the spine. Eligible participants are girls aged 2 to under 4 years old with a confirmed diagnosis of Rett syndrome due to a specific gene mutation. Participants should live close to the study site for easy access to visits and follow-ups. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether participants need to stop taking their current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies have shown that TSHA-102 is generally well-tolerated. In earlier research with adults, no serious side effects were linked to the treatment. Specifically, two patients who received TSHA-102 experienced no serious negative reactions. This suggests that the treatment is safe for humans so far. However, research is ongoing, and this trial will provide more information on safety in children with Rett syndrome.¹²³⁴⁵

Unlike the standard treatments for Rett Syndrome, which often focus on managing symptoms with medications like antiepileptic drugs and supportive therapies, TSHA-102 is a gene therapy designed to address the condition at its core. It works by using an innovative gene delivery method that introduces a functional version of the MECP2 gene directly into the patient's brain cells. Researchers are excited about TSHA-102 because it targets the genetic root of Rett Syndrome, offering potential for a more profound and lasting impact than current symptomatic treatments.

Research has shown that TSHA-102, which participants in this trial will receive, is designed to address the genetic cause of Rett syndrome by managing the MECP2 gene, crucial for brain function. Early results from previous patients have been promising, with improvements in movement and no serious side effects reported. Specifically, patients treated with TSHA-102 in earlier studies showed significant positive changes, such as better motor skills. This gene therapy is intended as a one-time treatment, offering a potentially lasting effect. Overall, the evidence so far supports optimism about TSHA-102's effectiveness for Rett syndrome.¹⁴⁶⁷⁸